Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial.
Adrien HolzgreveMarcus UnterrainerJérémie CalaisThaiza AdamsDaniela E Oprea-LagerKarolien GoffinEgesta LopciLena M UnterrainerKristina K M KramerNina-Sophie Schmidt-HegemannJozefina CasuscelliChristian G StiefJens RickePeter BartensteinWolfgang G KunzDirk MehrensPublished in: European journal of nuclear medicine and molecular imaging (2023)
We assume that the use of PSMA PET/CT is appropriate from a health economic perspective, but this will need to be verified by a prospective evaluation of patients at initial diagnosis.